Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 12, 2007, Pages 2024-2036

  Cai, Weibo ^a   Ebrahimnejad, Alireza ^a   Chen, Kai ^a   Cao, Qizhen ^a   Li, Zi Bo ^a   Tice, David A ^b   Chen, Xiaoyuan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDIMMUNE   (United States)

Author keywords

64Cu; EphA2 receptor tyrosine kinase; Humanized monoclonal antibody; Positron emission tomography; RadioimmunoPET

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; CHELATING AGENT; COPPER 64; EPHRIN RECEPTOR A2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1C1; MONOCLONAL ANTIBODY 1C1 CU 64; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG UPTAKE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RADIOIMMUNOASSAY; RAT; SIGNAL TRANSDUCTION; VALIDATION PROCESS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, NUDE; NEOPLASMS; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; RADIOPHARMACEUTICALS; RECEPTOR, EPHA2; TISSUE DISTRIBUTION;

EID: 36148975921     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0503-5     Document Type: Article

References (41)

1. Cheng N, Brantley DM, Chen J. The ephrins and Eph receptors in angiogenesis. Cytokine Growth Factor Rev 2002;13:75-85.
2. Brantley-Sieders D, Schmidt S, Parker M, Chen J. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des 2004;10:3431-42.
3. Gale NW, Holland SJ, Valenzuela DM, Flenniken A, Pan L, Ryan TE, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 1996;17:9-19.
4. Wang HU, Chen ZF, Anderson DJ. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 1998;93:741-53.
5. Saito T, Masuda N, Miyazaki T, Kanoh K, Suzuki H, Shimura T, et al. Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis. Oncol Rep 2004;11:605-11.
6. Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41:275-80.
7. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 2001;61:2301-6.
8. Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, et al. EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10:5145-50.
9. Kinch MS, Moore MB, Harpole DH, Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 2003;9:613-8.
10. Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets 2005;5:149-57.
11. Carles-Kinch K, Kilpatrick KE, Stewart JC, Kinch MS. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res 2002;62:2840-7.
12. Landen CN Jr, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst 2006;98:1558-70.
13. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005;65:6910-8.
14. Nasreen N, Mohammed KA, Antony VB. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006;107:2425-35.
15. Brantley DM, Cheng N, Thompson EJ, Lin Q, Brekken RA, Thorpe PE, et al. Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 2002;21:7011-26.
16. Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res 2004;64:910-9.
17. Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum GW, Qi-Werdich X, et al. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res 2006;82:664-73.
18. Noblitt LW, Bangari DS, Shukla S, Knapp DW, Mohammed S, Kinch MS, et al. Decreased tumorigenic potential of EphA2-overexpressing breast cancer cells following treatment with adenoviral vectors that express EphrinA1. Cancer Gene Ther 2004;11:757-66.
19. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem 2002;277:46974-9.
20. Alves PM, Faure O, Graff-Dubois S, Gross DA, Cornet S, Chouaib S, et al. EphA2 as target of anticancer immunotherapy: identification of HLA-A*0201-restricted epitopes. Cancer Res 2003;63:8476-80.
21. Guo H, Miao H, Gerber L, Singh J, Denning MF, Gilliam AC, et al. Disruption of EphA2 receptor tyrosine kinase leads to increased susceptibility to carcinogenesis in mouse skin. Cancer Res 2006;66:7050-8.
22. Cai W, Rao J, Gambhir SS, Chen X. How molecular imaging is speeding up anti-angiogenic drug development. Mol Cancer Ther 2006;5:2624-33.
23. 3. Cancer Res 2006;66:9673-81.
24. Cai W, Chen K, Mohamedali KA, Cao Q, Gambhir SS, Rosenblum MG, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006;47:2048-56.
25. Meares CF, McCall MJ, Reardan DT, Goodwin DA, Diamanti CI, McTigue M. Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal Biochem 1984;142:68-78.
26. 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. J Nucl Med 2007;48:304-10.
27. 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging 2007;34:850-8.
28. Ebrahimnejad A, Flayeh R, Unteregger G, Wagener C, Brummer J. Cell adhesion molecule CEACAM1 associates with paxillin in granulocytes and epithelial and endothelial cells. Exp Cell Res 2000;260:365-73.
29. Sgouros G. Dosimetry of internal emitters. J Nucl Med 2005;46 Suppl 1:18S-27S.
30. Anderson CJ, Connett JM, Schwarz SW, Rocque PA, Guo LW, Philpott GW, et al. Copper-64-labeled antibodies for PET imaging. J Nucl Med 1992;33:1685-91.
31. Cutler PD, Schwarz SW, Anderson CJ, Connett JM, Welch MJ, Philpott GW, et al. Dosimetry of copper-64-labeled monoclonal antibody 1A3 as determined by PET imaging of the torso. J Nucl Med 1995;36:2363-71.
32. Kataoka H, Igarashi H, Kanamori M, Ihara M, Wang JD, Wang YJ, et al. Correlation of EPHA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci 2004;95:136-41.
33. Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000;19:6043-52.
34. Kiewlich D, Zhang J, Gross C, Xia W, Larsen B, Cobb RR, et al. Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. Neoplasia 2006;8:18-30.
35. 18F-FBEM), and the synthesis of RGD peptide-based tracer for PET imaging of avb3 integrin expression. J Nucl Med 2006;47:1172-80.
36. Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X, et al. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007;2:47-52.
37. 67/64Cu-labeled anti-L1-CAM antibody chCE7: selection of copper ligands and PET imaging. Nucl Med Biol 2003;30:417-27.
38. 177Lu-DOTA-labeled aglycosylated monoclonal anti-L1-CAM antibody chCE7: influence of the number of chelators on the in vitro and in vivo properties. Nucl Med Biol 2006;33:883-9.
39. Sharkey RM, Cardillo TM, Rossi EA, Chang CH, Karacay H, McBride WJ, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5.
40. Paganelli G, Chinol M. Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Eur J Nucl Med Mol Imaging 2003;30:773-6.
41. Liu G, He J, Dou S, Gupta S, Rusckowski M, Hnatowich DJ. Further investigations of morpholino pretargeting in mice-establishing quantitative relations in tumor. Eur J Nucl Med Mol Imaging 2005;32:1115-23.